JP2022532431A - イマチニブ製剤、その製造および使用 - Google Patents

イマチニブ製剤、その製造および使用 Download PDF

Info

Publication number
JP2022532431A
JP2022532431A JP2021568694A JP2021568694A JP2022532431A JP 2022532431 A JP2022532431 A JP 2022532431A JP 2021568694 A JP2021568694 A JP 2021568694A JP 2021568694 A JP2021568694 A JP 2021568694A JP 2022532431 A JP2022532431 A JP 2022532431A
Authority
JP
Japan
Prior art keywords
imatinib
inhalable
salt
formulation
inhalable formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532431A5 (https=
Inventor
ベン デイク，
ラルフ ニーブン，
アンドリュー ディー． レビン，
Original Assignee
エアロベイト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアロベイト セラピューティクス， インコーポレイテッド filed Critical エアロベイト セラピューティクス， インコーポレイテッド
Publication of JP2022532431A publication Critical patent/JP2022532431A/ja
Publication of JP2022532431A5 publication Critical patent/JP2022532431A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021568694A 2019-05-16 2020-05-14 イマチニブ製剤、その製造および使用 Pending JP2022532431A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962849058P 2019-05-16 2019-05-16
US201962849054P 2019-05-16 2019-05-16
US201962849056P 2019-05-16 2019-05-16
US201962849059P 2019-05-16 2019-05-16
US62/849,054 2019-05-16
US62/849,059 2019-05-16
US62/849,056 2019-05-16
US62/849,058 2019-05-16
US201962877575P 2019-07-23 2019-07-23
US62/877,575 2019-07-23
US201962942408P 2019-12-02 2019-12-02
US62/942,408 2019-12-02
US202062958481P 2020-01-08 2020-01-08
US62/958,481 2020-01-08
US202062984037P 2020-03-02 2020-03-02
US62/984,037 2020-03-02
PCT/US2020/032872 WO2020232236A1 (en) 2019-05-16 2020-05-14 Imatinib formulations, manufacture, and uses thereof

Publications (2)

Publication Number Publication Date
JP2022532431A true JP2022532431A (ja) 2022-07-14
JP2022532431A5 JP2022532431A5 (https=) 2023-05-12

Family

ID=73228465

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021568694A Pending JP2022532431A (ja) 2019-05-16 2020-05-14 イマチニブ製剤、その製造および使用

Country Status (14)

Country Link
US (13) US20200360477A1 (https=)
EP (2) EP3968963A4 (https=)
JP (1) JP2022532431A (https=)
KR (1) KR20220050839A (https=)
CN (1) CN114514016A (https=)
AU (1) AU2020274521A1 (https=)
BR (1) BR112021023014A2 (https=)
CA (1) CA3140641A1 (https=)
IL (1) IL288111A (https=)
JO (1) JOP20210305A1 (https=)
MX (1) MX2021014029A (https=)
SG (1) SG11202112719XA (https=)
WO (2) WO2020232236A1 (https=)
ZA (1) ZA202109070B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230008354A (ko) * 2021-07-07 2023-01-16 애니머스큐어 주식회사 이마티닙을 포함하는 근육 질환의 예방 또는 치료용 조성물

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US20200360477A1 (en) * 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Inhalable formulations for kinase inhibition
CN116916889A (zh) * 2020-11-17 2023-10-20 联合治疗公司 用于肺高压领域的吸入式伊马替尼
EP4247378A4 (en) * 2020-11-23 2024-08-14 Aerovate Therapeutics, Inc. IMATINIB FORMULATIONS, MANUFACTURE AND USES THEREOF
CN117098557A (zh) * 2020-11-23 2023-11-21 埃渃维特治疗学公司 伊马替尼调配物、其制备和用途
CA3204054A1 (en) * 2021-01-06 2022-07-14 Carlos Schuler Inhalable imatinib formulation
CN117157076A (zh) * 2021-02-15 2023-12-01 埃渃维特治疗学公司 可吸入伊马替尼调配物、其制造和用途
EP4472609A1 (en) * 2022-02-04 2024-12-11 Justus-Liebig-Universität Gießen Inhaled imatinib for treatment of pulmonary hypertension

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007308494A (ja) * 2006-05-15 2007-11-29 Chemagis Ltd 結晶イマチニブ塩基及びその製造方法
JP2009514988A (ja) * 2006-10-26 2009-04-09 シコール インコーポレイティド イマチニブ塩基及びイマチニブメシレート、及びそれらの調製方法
WO2011157450A1 (en) * 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
WO2012090221A1 (en) * 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
US20130060030A1 (en) * 2010-03-15 2013-03-07 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
CN103910711A (zh) * 2014-03-24 2014-07-09 福建天泉药业股份有限公司 一种伊马替尼游离碱晶型及其制备方法
JP2016527275A (ja) * 2013-07-31 2016-09-08 ウインドワード ファーマ，インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2016534153A (ja) * 2013-10-11 2016-11-04 ローレンス エス． ジスマン， 噴霧乾燥製剤

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
WO2004004644A2 (en) * 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
GB2398565A (en) 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
US20040204439A1 (en) 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
ATE481134T1 (de) 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
US7507821B2 (en) 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
SI1833815T1 (sl) 2004-12-30 2011-01-31 Inst Farmaceutyczny Postopek priprave baze imatiniba
EP1695728A1 (de) 2005-02-23 2006-08-30 Activaero GmbH Bauteil für eine Inhalationsvorrichtung, Inhalationsvorrichtung mit diesem Bauteil und Steuerverfahren für ein solches Bauteil
EP1700614B1 (de) 2005-03-08 2013-05-08 Activaero GmbH Inhalationsvorrichtung
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
ATE373498T1 (de) 2005-07-06 2007-10-15 Activaero Gmbh Regelbares ventil und inhalationsvorrichtung
WO2007050783A2 (en) 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
CA2550702A1 (en) 2006-03-24 2007-09-24 Kensuke Egashira Organic compounds
WO2008011051A1 (en) 2006-07-17 2008-01-24 Liquidia Technologies, Inc. Nanoparticle fabrication methods, systems, and materials
EP2009008A1 (en) * 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
US20130177598A1 (en) * 2007-02-27 2013-07-11 The University Of North Carolina At Chapel Hill Discrete size and shape specific pharmaceutical organic nanoparticles
WO2008136010A1 (en) 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
EP2179291B1 (en) 2007-07-13 2014-10-22 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
ES2398921T3 (es) 2007-08-02 2013-03-22 Activaero Gmbh Dispositivo y sistema para dirigir partículas aerosolizadas a un área específica de los pulmones
EP2033674A1 (de) 2007-09-06 2009-03-11 Activaero GmbH Inhalationsgerät
KR20110053354A (ko) 2008-08-13 2011-05-20 노파르티스 아게 폐동맥 고혈압의 치료
US8834848B2 (en) 2009-02-04 2014-09-16 Activaero Gmbh Research & Development Flow and volume regulated inhalation for treatment of severe oral corticosteroid-dependent asthma
US20100330130A1 (en) 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
US20130034534A1 (en) 2009-09-29 2013-02-07 Philipp Kroneberg Method for treatment of patients with cystic fibrosis
WO2011039782A1 (en) 2009-09-29 2011-04-07 Ind-Swift Laboratories Limited Processes for preparing imatinib and pharmaceutically acceptable salts thereof
US20110306763A1 (en) 2009-12-10 2011-12-15 Shanghai Parling Pharmatech Co., Ltd. Process for the preparation of imatinib and salts thereof
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011100282A2 (en) 2010-02-09 2011-08-18 Dr. Reddy's Laboratories Ltd. Imatinib mesylate polymorphs
TR201007005A2 (tr) 2010-08-23 2011-09-21 Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. İmatinib baz üretim yöntemi
WO2012106382A1 (en) 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
PT2701683T (pt) 2011-04-26 2017-05-03 Vectura Gmbh Administração de iloprost como bólus de aerossol
EP2724741B1 (en) 2012-10-26 2017-06-14 Vectura GmbH Inhalation device for use in aerosol therapy
EP2846859B1 (en) 2012-03-09 2017-01-04 Vectura GmbH Mixing channel for an inhalation device and inhalation device
CN103570676B (zh) * 2012-08-04 2016-03-16 正大天晴药业集团股份有限公司 甲磺酸伊马替尼α结晶的制备及其药物组合物
EP2895146A1 (en) * 2012-09-17 2015-07-22 BIND Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
WO2014067699A1 (en) 2012-10-31 2014-05-08 Activaero Gmbh Administration of aerosolised iloprost
ES2675720T3 (es) 2013-01-10 2018-07-12 Pulmokine, Inc. Inhibidores de quinasa no selectivos
EP2988738A4 (en) * 2013-01-10 2016-11-09 Pulmokine Inc THERAPEUTIC INDICATIONS OF KINASE INHIBITORS
JP6401273B2 (ja) 2013-08-16 2018-10-10 ベクチュラ・ゲーエムベーハー 吸入装置用投与システム
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2015188243A1 (en) * 2014-06-10 2015-12-17 Cristália Produtos Químicos Farmacêuticos Ltda PROCESS FOR PREPARING IMATINIB AND IMATINIB MESYLATE NON-NEEDLE SHAPED α2 FORM
US10561805B2 (en) 2014-10-10 2020-02-18 Ablynx N.V. Methods of treating RSV infections
KR20180050320A (ko) 2015-09-09 2018-05-14 노파르티스 아게 분무-건조된 제제의 폐로의 표적화된 전달
EP3689339B1 (en) 2015-09-09 2022-01-26 Vectura Limited Jet milling method
AU2017351638A1 (en) 2016-10-26 2019-06-13 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
US10788268B2 (en) 2017-09-19 2020-09-29 Evapco, Inc. Air-cooled heat transfer device with integrated and mechanized air pre-cool system
EP3841090A4 (en) 2018-08-22 2022-10-19 Avalyn Pharma Inc. SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS
US20200360477A1 (en) * 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Inhalable formulations for kinase inhibition
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007308494A (ja) * 2006-05-15 2007-11-29 Chemagis Ltd 結晶イマチニブ塩基及びその製造方法
JP2009514988A (ja) * 2006-10-26 2009-04-09 シコール インコーポレイティド イマチニブ塩基及びイマチニブメシレート、及びそれらの調製方法
US20130060030A1 (en) * 2010-03-15 2013-03-07 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
WO2011157450A1 (en) * 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
WO2012090221A1 (en) * 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
JP2016527275A (ja) * 2013-07-31 2016-09-08 ウインドワード ファーマ，インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2016534153A (ja) * 2013-10-11 2016-11-04 ローレンス エス． ジスマン， 噴霧乾燥製剤
CN103910711A (zh) * 2014-03-24 2014-07-09 福建天泉药业股份有限公司 一种伊马替尼游离碱晶型及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230008354A (ko) * 2021-07-07 2023-01-16 애니머스큐어 주식회사 이마티닙을 포함하는 근육 질환의 예방 또는 치료용 조성물
KR102634754B1 (ko) 2021-07-07 2024-02-08 애니머스큐어 주식회사 이마티닙을 포함하는 근육 질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
CN114514016A (zh) 2022-05-17
US20220218706A1 (en) 2022-07-14
KR20220050839A (ko) 2022-04-25
US20200360279A1 (en) 2020-11-19
US11806349B2 (en) 2023-11-07
US20200360377A1 (en) 2020-11-19
ZA202109070B (en) 2023-01-25
US11298355B2 (en) 2022-04-12
US20200360277A1 (en) 2020-11-19
US20230086230A1 (en) 2023-03-23
US11229650B2 (en) 2022-01-25
EP3968963A4 (en) 2023-02-01
US20200360477A1 (en) 2020-11-19
BR112021023014A2 (pt) 2022-02-08
SG11202112719XA (en) 2021-12-30
EP3968963A1 (en) 2022-03-23
US20200360275A1 (en) 2020-11-19
WO2020232238A1 (en) 2020-11-19
EP3969111A1 (en) 2022-03-23
US20200360276A1 (en) 2020-11-19
US20240108622A1 (en) 2024-04-04
IL288111A (en) 2022-01-01
US11413289B2 (en) 2022-08-16
US20220184080A1 (en) 2022-06-16
US20230056721A1 (en) 2023-02-23
US11813263B2 (en) 2023-11-14
AU2020274521A1 (en) 2021-12-16
CA3140641A1 (en) 2020-11-19
EP3969111A4 (en) 2023-08-16
JOP20210305A1 (ar) 2023-01-30
US20240041879A1 (en) 2024-02-08
WO2020232236A1 (en) 2020-11-19
MX2021014029A (es) 2022-02-21
US20200360376A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
JP2022532431A (ja) イマチニブ製剤、その製造および使用
JP6082049B2 (ja) 閉塞性または炎症性気道疾患を治療するための２種以上の活性成分を含有する粒子の乾燥粉末製剤
CN104203284B (zh) 吸入用吡咯衍生物干粉制剂
CN102946868B (zh) 包含抗毒蕈碱药的干粉制剂
US11464776B2 (en) Inhalable imatinib formulations, manufacture, and uses thereof
JP6883039B2 (ja) 呼吸域ザフィルルカスト粒子の調製方法
JP2023171770A (ja) クロファジミンの吸入可能な組成物およびその使用方法
CN117241786A (zh) 使用基于悬浮液的薄膜冷冻制备干燥粉末的方法
CA3260232A1 (en) CRYSTALLINE PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING PARTICLES COMPOSITE OF SUGAR AND LIPID AND MANUFACTURING PROCESS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230501

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241008